Boundless Bio reports $127mln cash, BBI-355/BBI-825 combo open for enrollment.

• BBI-355/BBI-825 combination arm open for enrollment in POTENTIATE trial • BBI-940 on track for submission in H1 2026 • $127M in cash supports operations into H1 2028 • Expected proof-of-concept clinical readouts for both programs • Boundless Bio prioritizes strongest scientific rationale and greatest potential to impact patients with oncogene-amplified cancers.

San Diego, CA — Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on developing transformative therapies for oncogene-amplified cancers, has announced significant milestones in its research and development efforts. The company's latest updates highlight its commitment to advancing its pipeline of ecDNA-directed therapeutic candidates (ecDTx) and maintaining a robust financial position.

Clinical Trial Milestones

Boundless Bio has opened the BBI-355/BBI-825 combination arm of the POTENTIATE trial for enrollment. This combination therapy, which targets checkpoint kinase 1 (CHK1) and ribonucleotide reductase (RNR), is designed to provide synergistic anti-tumor activity without overlapping toxicity. The company expects to deliver initial proof-of-concept clinical data within its existing cash runway timeline [1].

Additionally, Boundless Bio is on track to submit an investigational new drug (IND) application for BBI-940, a kinesin degrader, in the first half of 2026. This novel program targets a previously undrugged kinesin and is expected to deliver initial proof-of-concept clinical data within the same timeframe [1].

Financial Position

As of June 30, 2025, Boundless Bio reported a cash position of $127.1 million, providing sufficient funding to support operations into the first half of 2028. This includes the expected proof-of-concept clinical readouts for both the BBI-355/BBI-825 combination and BBI-940 [1].

Research and Development (R&D) expenses for the second quarter of 2025 totaled $12.2 million, a decrease of $2.5 million compared to the same period in 2024. General and Administrative (G&A) expenses were $4.8 million, up from $4.7 million in the previous year [1].

Forward-Looking Statements

Boundless Bio cautions investors that statements regarding its expected cash runway, the timing of data readouts, and the submission of an IND application for BBI-940 are forward-looking and subject to risks and uncertainties. The company's approach to discovering and developing ecDTx is novel and unproven, and results from preclinical studies or early clinical trials may not be predictive of future results [1].

Investor Contacts

For more information, please contact James Lee at jlee@boundlessbio.com or Renee Leck at renee@thrustsc.com.

References

[1] https://www.marketscreener.com/news/boundless-bio-reports-second-quarter-2025-financial-results-and-business-highlights-ce7c5edbd18eff27